PHASE II CLINICAL TRIAL OF IMMUNOTHERAPY WITH AN ALLOGENEIC B7.1/HLA-A1 TRANSFECTED TUMOR CELL VACCINE (PT 107) IN PATIENTS WITH STAGES IIIB/IV NON-SMALL CELL LUNG CANCER THAT HAVE COMPLETED FIRST LINE CHEMOTHERAPY.
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2017
At a glance
- Drugs PT 107 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Nov 2017 According to a Pique Therapeutics media release, data will be presented at at the Society for the Immunotherapy of Cancer's (SITC) 32nd Annual Meeting.
- 07 Nov 2017 Results presented in a Pique Therapeutics Media Release.
- 27 Oct 2011 Status changed from not yet recruiting to recruiting as reported by Clinical Trials Registry - India.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History